CiplaCPLFY 92 Return-on-Tangible-Equity is 8.04% as of Mar. 2026, which is 51% below its 10-year median of 16.57. GuruFocus rates CPLFY with a GF Score™ of 92/100. The stock has 5 warning signs investors should review. Among 898 Drug Manufacturers companies, Cipla ranks better than 68.71% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Cipla's annualized net income for the quarter that ended in Mar. 2026 was $239.02 Mil. Cipla's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $2,971.56 Mil. Therefore, Cipla's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 8.04%.
The historical rank and industry rank for Cipla's Return-on-Tangible-Equity or its related term are showing as below:
CPLFY'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 14.42 Med: 16.57 Max: 21.88
Current: 14.31
During the past 13 years, Cipla's highest Return-on-Tangible-Equity was 21.88%. The lowest was 14.42%. And the median was 16.57%.
CPLFY's Return-on-Tangible-Equity is ranked better than 68.71% of 898
companies
in the Drug Manufacturers industry
Industry Median: 7.88
vs CPLFY: 14.31
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Cipla Return-on-Tangible-Equity Related Terms
Cipla Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Cipla's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CPLFY vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cipla's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cipla Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cipla's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Cipla's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 8.04% mean?
Cipla (CPLFY) has a Return-on-Tangible-Equity of 8.04% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Cipla and its competitors. This is 51% below median its historical median of 16.57. Over the past decade, Cipla's Return-on-Tangible-Equity has ranged from 14.42 to 21.88. According to the industry distribution chart, Cipla ranks #281 out of 898 companies in the Drug Manufacturers industry, placing it in the top 31.3%.
Is Cipla's Return-on-Tangible-Equity too high?
Cipla's current Return-on-Tangible-Equity of 8.04% is 51% below median its 10-year median of 16.57. Over the past 10 years, this metric has ranged from a low of 14.42 to a high of 21.88. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.88. Cipla's value of 8.04% is 2% above this industry median. Based on the distribution chart, Cipla ranks #281 out of 898 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cipla has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does Cipla's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cipla ranks #281 out of 898 companies for Return-on-Tangible-Equity. This puts Cipla in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.88. Cipla's value of 8.04% is 2% above this benchmark. Historically, Cipla's own Return-on-Tangible-Equity has ranged from 14.42 to 21.88 over the past decade. While the company's 10-year median is 16.57 vs. the industry median of 7.88, Cipla has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.88, based on 898 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cipla's current Return-on-Tangible-Equity of 8.04% is 2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Cipla and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cipla's current Return-on-Tangible-Equity is 8.04%, which is 51% below median its own 10-year median of 16.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipla stock overvalued right now?
Cipla (CPLFY) has a current Return-on-Tangible-Equity of 8.04%. The current Return-on-Tangible-Equity is 8.04%, which is 51% below median its 10-year median of 16.57 and 2% above the Drug Manufacturers industry median of 7.88. Cipla's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Cipla (CPLFY), the current Return-on-Tangible-Equity is 8.04% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPLFY has been successfully added to your 